---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-012762"
form_type: "8-K"
ticker: "MRAI"
cik: "0001844392"
company_name: "Marpai, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:50:52.431832+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marpai secures $1.7M revenue-based financing; amends AXA purchase deal to potentially reduce $3M obligation

## Summary
- Entered Libertas revenue-based financing: sold $2.193M future receipts for $1.7M; weekly payments over 9 months.
- AXA amendment reduces 2024 payment to $473,688 and defers further payments to 2025.
- Potential $3M reduction in AXA purchase price if CEO invests $3M equity, Nasdaq listing maintained, and payments made.
- CEO Damien Lamendola guarantees Libertas funding; also commits to $3M equity investment in 2024.
- Company expects to use Libertas proceeds for short-term working capital needs.

## SEC filing metadata
- accession: 0000950170-24-012762
- form_type: 8-K
- ticker: MRAI
- cik: 0001844392
- company_name: Marpai, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/0000950170-24-012762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/mrai-20240205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-012762
- JSON: https://secwatch.observer/filing/0000950170-24-012762.json
- Plain text: https://secwatch.observer/filing/0000950170-24-012762.txt

## Key facts
- Material Agreements
  Marpai, Inc. amended Amendment No. 1 to Purchase Agreement with AXA S.A. (effective 2024-02-07).
  - Action: amendment
  - Counterparty: AXA S.A.
  - Effective: 2024-02-07
  source text: On February 7, 2024, Marpai, Inc. (the “Company”) entered into Amendment No. 1 to Purchase Agreement (the “AXA Amendment”) with AXA S.A., a French société anonyme (“AXA”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/0000950170-24-012762-index.htm
- Material Agreements
  Marpai, Inc. entered into Agreement of Sale of Future Receipts with Libertas Funding LLC valued at $2,193,000 (effective 2024-02-05).
  - Action: entry
  - Counterparty: Libertas Funding LLC
  - Value: $2,193,000
  - Effective: 2024-02-05
  source text: On February 5, 2024, the Company entered into an Agreement of Sale of Future Receipts (the “Libertas Agreement”) with Libertas Funding LLC (“Libertas”) to sell future receipts totaling $2,193,000 for a purchase price of $1,700,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844392/000095017024012762/0000950170-24-012762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.